RepathaA can lead to decrease of atherosclerosis in CAD patients

Amgen's addition of RepathaA (evolocumab) to optimized statin therapy has resulted in a noteworthy statistical decrease of atherosclerosis in patients who have coronary artery disease.
The results of the Phase 3 GLAGOV coronary intravascular ultrasound imaging study were presented at the American Heart Association (AHA) Scientific Sessions 2016 at a Late-Breaking Clinical trials Session. The results of the trial were also published in the Journal of the American Medical Association.
“The cardiovascular community began conducting imaging studies with LDL-C therapies to measure slowing of atherosclerotic disease progression. This study shows that maximal LDL-C reduction with Repatha can actually regress coronary atherosclerotic disease compared to statins alone,” Amgen Executive Vice President of Research and Development Dr. Sean Harper said. “In fact, nearly two-thirds of patients on Repatha in this trial, the vast majority of whom were already on high to moderate intensity statin therapy at baseline, experienced a reduction in plaque burden.”
Repatha was the object of study in the GLAGOV trial, which assessed whether the drug could alter atherosclerotic plaque that has been built up in the coronary arteries of patients who have had prior treatments with optimized statin therapy.